"Nothing in Nature functions in isolation, systems need to be considered as a whole, although not necessarily in every details. Mathematical models provide a way to capture the essence of interactions and behaviors of a complex system, which can then be systematically interrogated to generate new insight and guidance."
I joined Genentech in February 2016 in the Modeling & Simulation group within Clinical Pharmacology, as a growing effort to expand the impact of Quantitative Systems Pharmacology (QSP) in the clinical development of our compounds. Our approach relies on a variety of quantitative methods such as mechanisms-based modeling, disease and pathway modeling, PKPD modeling, or any other quantitative approach that will help answer our questions of interest with speed and reliability. Being part of Clinical Pharmacology, the focus is on questions related to human dose selection, dose scheduling optimization, biomarkers characterization, treatment duration determination and patients stratification.
I use quantitative methods to help in the early clinical development of therapeutics, mostly in oncology and immune-oncology, but not only.
In the cancer immunotherapy space, we are developing a modeling platform to systematically evaluate combinations of immune checkpoint targets, with special interest in dose sequencing and scheduling optimization.
I am also involved in developing and refining QSP models to help mitigate adverse events from anticancer treatments by optimizing dosing, scheduling and the bio-therapeutics properties of the drugs. Our main focus is on drug-induced colitis and drug-induced neutropenia.
I have also a strong interest in the development and advancement of QSP methods, including emerging approaches in parameter estimation (in particular using global optimization techniques), data and knowledge collection, data integration, virtual population generation and calibration, and other modeling technical questions.
Another interest is in fostering strategies for implementation and deployment of QSP approaches within the company, for example by finding new ways to facilitate multidisciplinary collaborations, or by promoting educational activities around systems modeling.